¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"tissue thromboplastin inhibition time"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
¿µ¹® epithelial tissue ÇÑ±Û »óÇÇÁ¶Á÷
¼³¸í   
  »óÇǴ ÇÑ Ãþ ¶Ç´Â ¿©·¯ ÃþÀÇ ¼¼Æ÷·Î ÀÌ·ç¾îÁø ÆÇ ¸ð¾çÀÇ ±¸Á¶·Î ½ÅüÀǠǥ¸é°ú °ü»ó±¸Á¶ÀÇ ³»°­À» µÑ·¯½Î°í ÀÖ´Ù. »óÇǼ¼Æ÷¿Í »óÇǼ¼Æ÷»çÀÌÀÇ ÀûÀº ¾çÀ¸·Î Á¸ÀçÇÏ¿© »óÇÇ»çÀÌÀÇ °ø°£À» Ã¤¿ì°í Àִ ¼¼Æ÷°£ÁúÀ» ÇÕÃÄ »óÇÇÁ¶Á÷À̶ó ÇÑ´Ù. »óÇÇÁ¶Á÷¿¡´Â ¿øÄ¢ÀûÀ¸·Î Ç÷°üÀÌ ºÐÆ÷µÇ¾î ÀÖÁö ¾Ê´Ù.
¿µ¹® granulation tissue ÇÑ±Û À°¾ÆÁ¶Á÷
¼³¸í   
  ¸ð¼¼Ç÷°üÀ̠dzºÎÇϸ砿ռºÇϰԠÁõ½ÄÀ» °è¼ÓÇϴ ¾î¸° °áÇÕÁ¶Á÷. Ã¢»ó µî Á¶Á÷ °á¼Õ¿¡ ´ëÇÑ ¼öº¹, À̹°Ã³¸®ÀÇ ±âÁúÈ­, ¿°ÁõÀÌ ¸¸¼ºÀûÀΠ°æ°ú¿¡ Àְųª Á¾¾çÁõ½Ä¿¡ µ¿¹ÝµÈ »çÀ̹°ÁúÀÇ ¹ÝÀÀ¼º ¿°Áõ¿¡¼­ °üÂûµÈ´Ù. ±¸¼º¼ººÐÀº »ý±äÁö ¾ó¸¶ ¾ÈµÇ´Â ¾î¸° À°¾ÆÁ¶Á÷Àº ¼¶À¯¸ð¼¼Æ÷ÀÇ Áõ½Ä, »õ·Î »ý±ä ¸ð¼¼Ç÷°ü°ú ¿©·¯ À¯ÁÖ¼¼Æ÷ ¹× ´Ù¸¥ Áß°£¿±¼¼Æ÷(¹éÇ÷±¸, ¸²ÇÁ±¸, ÇüÁú¼¼Æ÷, Á¶Á÷±¸, ´ÜÇÙ±¸, °Å´ë¼¼Æ÷)µîÀ¸·Î ±¸¼ºµÈ´Ù. À̰ÍÀÌ ½Ã°£ÀÌ Áö³ª ±×¸®µÇ¸é, ¸ð¼¼Ç÷°ü°ú À¯ÁÖ¼¼·Î, ´Ù¸¥Á¶Á÷¼ººÐÀ» °¨¼Ò½ÃÄÑ ¸¸¼ºÈ­ÇÏ¿© ¿À·¡µÈ À°¾Æ°¡ µÇ¸ç °á±¹Àº ¼¶À¯¼¼Æ÷¿Í ¾Æ±³Áú¼¶À¯·Î ±¸¼ºµÈ ¹ÝÈçÁ¶Á÷À¸·Î º¯ÇÑ´Ù.
¿µ¹® tissue ÇÑ±Û Á¶Á÷
¼³¸í   
  Æ¯Á¤ ±¸Á¶¿Í ±â´ÉÀ» °®´Â ¼¼Æ÷ Áý´Ü. ¼¼Æ÷ »çÀÌ¿¡´Â ´Ù¼Ò°£ ¼¼Æ÷°£ÁúÀÌ µé¾î ÀÖ´Ù. ¼¼Æ÷°£Áú¿¡´Â ±Û¸®ÄÚ»ç¹Ì³ë±Û¸®Ä­, È÷µå·Ï½Ã¾ÆÆÄŸÀÌÆ®¿Í °°Àº ±âÁú°ú ¾Æ±³Áú¼¶À¯¿Í °°Àº ¼¶À¯°¡ ¹ß°ßµÈ´Ù. Á¶Á÷¼º»óÀº ±¸¼º¼¼Æ÷¿Í ¼¼Æ÷°£ÁúÀÇ Á¾·ù¿Í ¾ç¿¡ ÀÇÇØ °áÁ¤µÈ´Ù. Á¶Á÷Àº »óÇÇÁ¶Á÷, ÁöÁöÁ¶Á÷, ±ÙÀ°Á¶Á÷, ½Å°æÁ¶Á÷À¸·Î ´ëº°µÇ¸ç, »óÇÇÁ¶Á÷Àº ¼¼Æ÷°£ÁúÀ» °ÅÀÇ °®Áö ¾ÊÀ¸¸ç, ÁöÁöÁ¶Á÷Àº °áÇÕÁ¶Á÷À̳ª »ÀÁ¶Á÷°ú °°ÀÌ ¼¼Æ÷°£ÁúÀ̠dzºÎÇÑ °ÍÀÌ ¸¹´Ù.
¿µ¹® tissue biopsy ÇÑ±Û Á¶Á÷»ý°Ë
¼³¸í   
  È¯ÀÚÀÇ º´ÀûÀΠÁ¶Á÷ÀÇ ÀϺθ¦ ¶¼¾î ³»¼­ º´¸®Á¶Á÷Ç¥º»À» ¸¸µé¾î¼­ Çö¹Ì°æÀûÀ¸·Î °Ë»çÇϴ °Í. ¿Ü°úÀû ¼ö¼úÀç·á·ÎºÎÅÍ º´¸®Á¶Á÷ÇÐÀû °Ë»ç¸¦ ÇÏ¿© »ýü³»ÀÇ º´º¯À» Ãß±¸Çϴ ºÐ¾ß¸¦ ¿Ü°úº´¸®ÇÐÀ̶ó°í ÇÑ´Ù. »ý°Ë¿¡´Â ½û±â»ý°Ë, ÃµÀÚħ»ý°Ë, ²ç¶Õ±â½Ä»ý°Ë, ³»½Ã°æ»ý°Ë ¿Ü¿¡ ¼¼Æ÷ÁøÀ̶ó°í ºÒ¸®¿ì´Â ¹Ú¸®¼¼Æ÷ÁøÀ̳ª ¼¼Ã´¼¼Æ÷Áø µî ¶³¾îÁø ¼¼Æ÷¸¦ µµ¸»°Ë»çÇϴ ¹æ¹ýÀÌ Æ÷ÇԵȴÙ.
¿µ¹® target tissue ÇÑ±Û Ç¥ÀûÁ¶Á÷
¼³¸í   
  È£¸£¸ó¿¡ ´ëÇÏ¿© Ç¥ÀûÀÌ µÇ´Â ¼¼Æ÷¶ó´Â Àǹ̷μ­ ±× È£¸£¸ó¿¡ ´ëÇÑ ¼ö¿ëü¸¦ °¡Áö°í Àִ ¼¼Æ÷. ¿¹¸¦ µé¾î Àν¶¸°Àº Àν¶¸° ¼ö¿ëü¸¦ °¡Áø ¼¼Æ÷¸¦ Ç¥Àû¼¼Æ÷·Î ÇÏ¿© ÀÌ ¼¼Æ÷¿¡¸¸ ÀÛ¿ëÇÑ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • hemagglutination inhibition test
    Ç÷±¸ÀÀÁý¾ïÁ¦°Ë»ç
  • hemagglutination-inhibition reaction
    ÀûÇ÷±¸ÀÀÁý¾ïÁ¦¹ÝÀÀ
  • irreversible inhibition
    ºñ°¡¿ª¾ïÁ¦
  • immunologic inhibition
    ¸é¿ª¾ïÁ¦
  • inhibition
    ¾ïÁ¦, ÀúÁö
  • inhibition reaction
    ¾ïÁ¦¹ÝÀÀ
  • inhibition test
    ¾ïÁ¦°Ë»ç
  • migration inhibition factor
    À̵¿ÀúÁöÀÎÀÚ
  • migration inhibition test
    À̵¿¾ïÁ¦°Ë»ç, À̵¿ÀúÁö°Ë»ç
  • noncompetitive inhibition
    ºñ°æÀï¾ïÁ¦
  • postsynaptic inhibition
    ½Ã³À½ºÀÌÈľïÁ¦, ¿¬Á¢ÀÌÈľïÁ¦
  • presynaptic inhibition
    ½Ã³À½ºÀÌÀü¾ïÁ¦, ¿¬Á¢ÀÌÀü¾ïÁ¦
  • reciprocal inhibition
    »ó¹Ý¾ïÁ¦, »óÈ£¾ïÁ¦
  • reciprocal inhibition psychotherapy
    »óÈ£¾ïÁ¦Á¤½Å¿ä¹ý, »ó¹Ý¾ïÁ¦Á¤½Å¿ä¹ý
  • recurrent inhibition
    ȸ±Í¾ïÁ¦
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • granulation tissue
    À°¾ÆÁ¶Á÷
  • interstitial tissue
    »çÀÌÁúÁ¶Á÷, °£ÁúÁ¶Á÷
  • lymphatic tissue
    ¸²ÇÁÁ¶Á÷
  • mesenchymal tissue
    Áß°£¿±Á¶Á÷
  • muscular tissue
    ±ÙÀ°Á¶Á÷
  • nervous tissue
    ½Å°æÁ¶Á÷
  • osseous tissue
    »ÀÁ¶Á÷
  • osteoid tissue
    »À¸ð¾çÁ¶Á÷, Dz»ÀÁ¶Á÷
  • retained placental tissue
    ÀÜ·ùŹÝÁ¶Á÷
  • reticular tissue
    ±×¹°Á¶Á÷, ¼¼¸ÁÁ¶Á÷
  • scar tissue
    ÈäÅÍÁ¶Á÷
  • soft tissue
    ¿¬Á¶Á÷, ¹°··Á¶Á÷
  • subcutaneous tissue
    ÇǺιØÁ¶Á÷, ÇÇÇÏÁ¶Á÷
  • tissue typing
    Á¶Á÷Çü°Ë»ç
  • time
    ½Ã°£
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • density dependent inhibition
    ¹ÐµµÀÇÁ¸¾ïÁ¦
  • enzyme inhibition
    È¿¼Ò¾ïÁ¦
  • feedback inhibition
    µÇ¸ÔÀÓ¾ïÁ¦
  • fertility inhibition
    ¼öÅÂÀÎÀÚÀü´ÞÀúÁö
  • migration inhibition factor
    Æ÷½Ä¼¼Æ÷À̵¿ÀúÇØÀÎÀÚ
  • hemagglutination inhibition test
    Ç÷±¸ÀÀÁý¾ïÁ¦°Ë»ç
  • hemagglutination-inhibition reaction
    ÀûÇ÷±¸ÀÀÁý¾ïÁ¦¹ÝÀÀ
  • inhibition
    ¾ïÁ¦, ÀúÁö
  • immunologic inhibition
    ¸é¿ª¾ïÁ¦
  • inhibition reaction
    ¾ïÁ¦¹ÝÀÀ, ÀúÁö¹ÝÀÀ
  • inhibition test
    ¾ïÁ¦°Ë»ç
  • inhibition zone
    ¾ïÁ¦¿µ¿ª
  • irreversible inhibition
    ºÒ°¡¿ªÀúÁö
  • noncompetitive inhibition
    ºñ°æÀï¾ïÁ¦
  • postsynaptic inhibition
    ¿¬Á¢ÈľïÁ¦, ½Ã³À½ºÈľïÁ¦
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • adipose tissue disease
    Áö¹æÁ¶Á÷Áúȯ.
  • angioblastic tissue
    Ç÷°ü¹ß»ýÁ¶Á÷
  • free water in stationary tissue
    Á¤Àû Á¶Á÷³» ÀÚÀ¯ ¼öºÐ
  • general connective tissue
    ÀϹݰáÇÕÁ¶Á÷.
  • gingival tissue esthetics
    Ä¡ÀºÁ¶Á÷½É¹Ì¼º.
  • granulation tissue
    À°¾ÆÁ¶Á÷(¡­ðÚòÄ)
  • gut-associated lymphatic tissue (GALT)
    Àå-¿¬°ü ¸²ÇÁÁ¶Á÷
  • hemopoietic tissue
    Ç÷__ü¼ºÁ¶Á__ Á¶Ç÷Á¶Á÷.
  • hemopoietic tissue
    Ç÷±¸Çü¼ºÁ¶Á÷
  • hemopoietic tissue
    Ç÷±¸Çü¼ºÁ¶Á÷, Á¶Ç÷Á¶Á÷.
  • hemopoietic tissue
    Ç÷¾×Çü¼ºÁ¶Á÷
  • immunity, tissue
    Á¶Á÷¸é¿ª
  • pigment connective tissue
    »ö¼Ò°áÇÕÁ¶Á÷
  • pigment tissue
    »ö¼ÒÁ¶Á÷(ßäáÈðÚòÄ).
  • placental tissue
    ŹÝÁ¶Á÷.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • plasma thromboplastin inhibitor
    ÇöóÁ <Ç÷Àå>Æ®·Òº¸ÇÃ¶ó½ºÆ¾¾ïÁ¦¹°Áú.
  • thromboplastin
    Æ®·Òº¸ÇÃ¶ó½ºÆ¾
  • thromboplastin
    Æ®·Òº¸ÇÃ¶ó½ºÆ¾.
  • thromboplastin generation test
    Æ®·Òº¸ÇÃ¶ó½ºÆ¾»ý¼º½ÃÇè(¡­ßæà÷ãËúÐ)
  • thromboplastin plasma component
    Ç÷¼ÒÆÇ¼º Ç÷À强ºÐ(úìá³÷ùàõúìíìà÷ÝÂ).
  • spongy bone tissue [trabecular bone tissue]
    ÇØ¸é»ÀÁ¶Á÷
  • afferent inhibition
    ±¸½É¼º ¾ïÁ¦(Ï´ãýàõåäð¤)
  • agar gel precipitin inhibition test
    ÇÑõ°Öħ°­¼Ò ÀúÁö½ÃÇè(¡­ ˽áÈðæò­ãËúÐ).
  • agglutination inhibition test
    ÀÀÁý¾ïÁ¦½ÃÇè(¡­åäð¤ãËúÐ).
  • allogen(a)ic inhibition
    µ¿Á¾¼¼Æ÷ÀúÁö(¡­á¬øàðæò­).
  • antidromic inhibition
    ¿ª¹æÇ⼺ ¾ïÁ¦ (¡­åäð¤)
  • cardiac inhibition
    ½ÉÀå ¾ïÁ¦(ãýíôåäð¤)
  • cell,contact inhibition
    Á¢Ã˾ïÁ¦ (ïÈõºåäð¤)
  • chemical inhibition isoagglutinin
    È­ÇÐÀû ¾ïÁ¦ µ¿Á¾ÀÀÁý¼Ò
  • colony inhibition
    ±ÕÁý¶ô¾ïÁ¦(жó¢Õªåäð¤), ±ºÃ¼¾ïÁ¦(ÏØô÷åäð¤).
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Conducting tissue of heart
    ½ÉÀåÀüµµÁ¶Á÷
    [¿¾ ¿ë¾î] ½ÉÀåÀüµµ°è
  • Collagenous connective tissue
    ¾Æ±³°áÇÕÁ¶Á÷
    [¿¾ ¿ë¾î] ±³¿ø°áÇÕÁ¶Á÷
  • Cartilage tissue
    ¿¬°ñÁ¶Á÷ [¹°··»ÀÁ¶Á÷]
    [¿¾ ¿ë¾î] ¿¬°ñÁ¶Á÷
  • Submucosal tissue
    Á¡¸·¹ØÁ¶Á÷
    [¿¾ ¿ë¾î] Á¡¸·ÇÏÁ¶Á÷
  • Abnormality of tissue
    Á¶Á÷ÀÌ»ó
    [¿¾ ¿ë¾î] Á¶Á÷ÀÌ»ó
  • Notochordal tissue (Chordoma)
    ô»èÁ¶Á÷ (ô»èÁ¾)
    [¿¾ ¿ë¾î] ô»èÁ¶Á÷
  • Lamellar bone tissue
    ÃþÆÇ»ÀÁ¶Á÷
    [¿¾ ¿ë¾î] ÃþÆÇ¼º°ñÁ¶Á÷
  • Compact bone tissue
    Ä¡¹Ð»ÀÁ¶Á÷
    [¿¾ ¿ë¾î] Ä¡¹Ð°ñÁ¶Á÷
  • Dense collagenous connective tissue
    Ä¡¹Ð¾Æ±³°áÇÕÁ¶Á÷
    [¿¾ ¿ë¾î] Ä¡¹Ð°áÇÕÁ¶Á÷
  • Renal tissue (Nephroblastoma)
    ÄáÆÏÁ¶Á÷ (ÄáÆÏ¸ð¼¼Æ÷Á¾)
    [¿¾ ¿ë¾î] ½ÅÁ¶Á÷
  • Elastic connective tissue
    ź·Â°áÇÕÁ¶Á÷
    [¿¾ ¿ë¾î] ź·Â°áÇÕÁ¶Á÷
  • Prechondral tissue
    Dz¿¬°ñÁ¶Á÷
    [¿¾ ¿ë¾î] Àü¿¬°ñÁ¶Á÷
  • Subcutaneous tissue
    ÇǺιØÁ¶Á÷
    [¿¾ ¿ë¾î] ÇÇÇÏÁ¶Á÷
  • Angioblastic tissue
    Ç÷°ü¹ß»ýÁ¶Á÷
    [¿¾ ¿ë¾î] Ç÷°ü¸ðÁ¶Á÷
  • Connective tissue fibers
    °áÇÕÁ¶Á÷¼¶À¯
    [¿¾ ¿ë¾î] °áÇÕÁ¶Á÷¼¶À¯
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • tissue plasminogen activator
    Á¶Á÷(ðÚòÄ)Çö󽺹̳ëÀü Ȱ¼ºÀÚ (üÀàõí­)
  • tissue polypeptide antigen
    Á¶Á÷(ðÚòÄ)Æú¸®ÆéŸÀ̵å Ç׿ø (ù÷ê«)
  • tissue slice
    Á¶Á÷ õ¿± (ðÚòÄô¼ç¨)
  • tissue-specific enzyme
    Á¶Á÷ ƯÀÌ È¿¼Ò (ðÚòÄ÷åì¶ý£áÈ)
  • white adipose tissue
    ÈØ Áö¹æÁ¶Á÷ (ò·Û¸ðÚòÄ)
  • assimilation time
    µ¿È­ÀÛ¿ë ½Ã°£ (ÔÒûùíÂéÄãÁÊà)
  • clotting time
    ÀÀ°í½Ã°£(ëêͳãÁÊà)
  • coincidence time
    µ¿½Ã½Ã°£(ÔÒãÁãÁÊà)
  • double beam in time spectrophotometer
    ½Ö±¤¼Ó ½Ã°£ ºÐ±¤±¤µµ°è(äªÎÃãÁÊàáÜÝÂÎÃÎÃÓøÍª)
  • elution time
    ¿ë¸® ½Ã°£ (éÁ×îãÁÊà)
  • fixed time assay
    ÀÏÁ¤½Ã°£(ìéïÒãÁÊà) ¾Æ½êÀÌ
  • generation time
    ¼¼´ë ½Ã°£(á¦ÓÛãÁÊà)
  • generation-time hypothesis
    ¼¼´ë ½Ã°£ ¼³(á¦ÓÛãÁÊààã)
  • half-reaction time
    ¹Ý¹ÝÀÀ ½Ã°£(ÚâÚãëëãÁÊà)
  • half-time
    ¹Ý ½Ã°£(ÚâãÁÊà)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • osseous tissue
    »ÀÁ¶Á÷, °ñÁ¶Á÷
  • osteoblastic tissue
    °ñÇü¼ºÁ¶Á÷
  • proper connective tissue
    °íÀ¯°áÇÕÁ¶Á÷
  • pseudogating in flowing tissue
    À¯µ¿Á¶Á÷¿¡¼­ À§°ÔÀÌÆÃ
  • reticular connective tissue
    ¼¼¸Á°áÇÕÁ¶Á÷
  • reticular tissue
    ¼¼¸ÁÁ¶Á÷
  • retropharyngeal soft tissue space
    ÀεÎÈĺο¬ºÎÁ¶Á÷
  • scar tissue
    ¹ÝÈçÁ¶Á÷
  • soft tissue
    ¿¬Á¶Á÷
  • soft tissue calcification
    ¿¬Á¶Á÷¼®È¸È­
  • soft tissue technique
    ¿¬Á¶Á÷±â¹ý
  • stationary tissue
    Á¤Á¶Á÷
  • surrounding tissue
    ÁÖÀ§Á¶Á÷
  • tissue
    Á¶Á÷
  • tissue anoxia
    Á¶Á÷¹«»ê¼ÒÁõ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
ST esotropia; scala tympani; scaphotrapezoid; sclerotherapy; sedimentation time; semitendinosus; sensor...
TT tablet triturate; tactile tension; tendon transfer; test tube; testicular torsion; tetanus toxin; te...
TI inversion time; temporal integration; terminal ileum; thalassemia intermedia; therapeutic index; tho...
EIC elastase inhibition capacity; enzyme inhibition complex
LAI latex particle agglutination inhibition; leukocyte adherence inhibition
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
ACEi Angiotensin I converting enzyme inhibition
BIS Behavioral Inhibition System
CEI Converting enzyme inhibition
DSI Depolarisation-induced suppression of inhibition
GI Growth inhibition
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • lateral inhibition
    Ãø¹æ ¾ïÁ¦
    ÈïºÐÇϰí ÀÖ´Â ¿ä¼Ò¿¡ ÀÇÇÏ¿© ÀÎÁ¢ÇÏ´Â ¿ä¼ÒÀÇ È°µ¿ÀÌ ¾ïÁ¦µÇ´Â Çö»ó.
  • lingering inhibition

    lingissimus capitis (µÎÃÖÀå±Ù

    »óÃø 4¡­5 ÈäÃßÀÇ È¾µ¹±â¿Í ÇÏÃø 3¡­4 °æÃßÀÇ °üÀýµ¹±â¿¡¼­ ±â½ÃÇÏ¿© ÃøµÎ°ñÀÇ À¯¾çµ¹±â¿¡¼­ Á¤ÁöÇÑ´Ù. °æ ½Å°æ °¡ÁöÀÇ Áö¹è¸¦ ¹ÞÀ¸¸ç, ¸Ó¸®¸¦ ÈĹæÀ¸·Î ´ç±â°í ȸÀü½ÃŲ´Ù.
  • myelinated afferent inhibition
    À¯¼öÃÊ ±¸½É¼º ¾ïÁ¦
  • negative feedback inhibition
    À½¼º µÇ¸ÔÀ̱⠾ïÁ¦
  • noncompetitive inhibition
    ºñ°æÇÕÀû ÀúÇØ
  • postsynaptic inhibition
    ½Ã³³½º ÈÄ ¾ïÁ¦
  • segmented inhibition
    ºÐÀýµÈ ¹æÇØ
  • self inhibition
    Àڱ⠾ïÁ¦
  • tonic inhibition
    ±äÀ强 ¾ïÁ¦
  • acquisition time
    ȹµæ ½Ã°£
  • activated coagulation time
    Ȱ¼º Ç÷¾× ÀÀ°í½Ã°£
  • area under the concentration-time curve
    Ç÷Áß ³óµµ °î¼±ÇÏ ¸éÀû, Ç÷Áß ¾à¹° ³óµµ °î¼±ÇÏ ¸éÀû
  • arm to lung time test
    ÆÈ Æó ¼øÈ¯ ½Ã°£ ½ÃÇè
  • arm-to-retina circulation time
    ÆÈ ¸Á¸· ¼øÈ¯ ½Ã°£
  • bleeding time test
    ÃâÇ÷ ½Ã°£ ½ÃÇè
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
residual inhibition The inhibition or suppression of tinnitus by use of a sound-generating device (residual inhibitor) which masks the sounds of tinnitus and produces a residual sound-inhibiting effect when the device is turned off.
(05 Mar 2000)
retroactive inhibition The partial or complete obliteration of memory by a more recent event, particularly new learning.
Compare: proactive inhibition.
(05 Mar 2000)
migration inhibition test A test which measures the presence of migration-inhibitory factor. Usually peritoneal macrophages are placed in a capillary tube in the presence or absence of supernatants from activated T-cells. If MIF is present, the migration of monocyte/macrophages is reduced.
Synonym: macrophage migration inhibition test, migration inhibition test.
(05 Mar 2000)
Wedensky inhibition Inhibition of muscle response resulting from application of a series of rapidly repeated stimuli to the motor nerve where slower frequency of stimulation results in muscle response.
(05 Mar 2000)
competitive inhibition <chemistry> Inhibitor that occupies the active site of an enzyme or the binding site of a receptor and prevents the normal substrate or ligand from binding.
at sufficiently high concentration of the normal ligand inhibition is lost: the Km is altered by the competitive inhibitor, but the Vmax remains the same.
(05 Jan 1998)
contact inhibition The inhibition of continued growth and division of a cell or colony due to physical contact with other cells or colonies. The stopping of continued growth when a certain density of cells has been reached.
The momentary stopping of all movement when a mobile cell runs into another cell.
(09 Oct 1997)
contact inhibition of growth See: density dependent inhibition.
(18 Nov 1997)
contact inhibition of movement Reaction in which the direction of motion of a cell is altered following collision with another cell. In heterologous contacts both cell may respond (mutual inhibition) or only one (nonreciprocal). Type I contact inhibition involves paralysis of the locomotory machinery, Type II is a consequence of adhesive preference for the substratum rather than the dorsal surface of the other cell.
(18 Nov 1997)
contact inhibition of phagocytosis Phenomenon described in sheets of kidney epithelial cells that, when confluent, lose their weak phagocytic activity, probably because of a failure of adhesion of particles to the dorsal surface in the absence of ruffles.
(18 Nov 1997)
haemagglutination inhibition A variation of the haemagglutination technique. Some viral antigens, when coated on erythrocytes, spontaneously cause agglutination in the absence of antibody. In these situations, the specific antigen-antibody reaction actually prevents the agglutination of reagent RBCs. Haemagglutination inhibition cannot differentiate between isotypes of specific antibodies (IgG, IgA or IgM) although positive haemagglutination inhibition analysis of specimens treated with Staphylococcus aureus Protein A (discussed above under coagglutination) to remove the IgG isotype antibodies has been used to imply the presence of specific IgM antibodies to the specific viral antigen. The crude quantitation of the specific antibodies is possible using serial dilution (titre).
(05 Mar 2000)
haemagglutination inhibition test <investigation> A clinical lab test used to detect the presence of a certain haemagglutinating virus or other haemagglutinin antigen based on whether the red blood cells in the sample lose the ability to clump together when the antibody to the virus or other antigen is added to it.
If the virus or antigen is present, the antibody kills it and thereby stops it from being able to stick the red blood cells to each other.
(09 Oct 1997)
haemagglutination inhibition tests Serologic tests in which a known quantity of antigen is added to the serum prior to the addition of a red cell suspension. Reaction result is expressed as the smallest amount of antigen which causes complete inhibition of haemagglutination.
(12 Dec 1998)
potassium inhibition Arrest of the heart in the fully relaxed state as a result of potassium intoxication.
(05 Mar 2000)
haptenic inhibition <immunology, molecular biology> Could be considered an isolated epitope: although a hapten (by definition) has an antibody directed against it, the hapten alone will not induce an immune response if injected into an animal, it must be conjugated to a carrier (usually a protein).
The hapten constitutes a single antigenic determinant, perhaps the best known example is dinitro phenol (DNP) that can be conjugated to BSA and against which antiDNP antibodies are produced (antibodies to the BSA can be adsorbed out).
Because the hapten is monovalent, immune complex formation will be blocked if the soluble hapten is present as well as the hapten carrier conjugate (assuming there is more than one hapten per carrier then an immune precipitate can be formed).
Competitive inhibition by the soluble small molecule is sometimes referred to as haptenic inhibition and this term has carried over into lectin mediated haemagglutination where monosaccharides are added to try to block haemagglutination: the blocking sugar defines the specificity of the lectin.
(18 Nov 1997)
hapten inhibition of precipitation Inhibition of precipitation that occurs when the precipitin has combined with hapten of the same specificity as the subsequently added antigen.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • at this time of ~
    ~ÀÇ À̸¾¶§
  • behind time
    ´ÊÀº
  • bide one's time
    ÁÁÀº½Ã±â¸¦ ±â´Ù¸®´Ù
  • by that time
    ±×¶§±îÁö
  • by the time
    ±×¶§Âë¿¡
  • by-time
    ¿©°¡
  • for the first time
    óÀ½À¸·Î
  • high time
    ²À ¾Ë¸ÂÀº ¶§
  • in time
    ½Ã°£¿¡ ¸Â°Ô
  • lose no time in
    °ð - ÇÏ´Ù
  • mark time
    Á¦ÀÚ¸® °ÉÀ½ÇÏ´Ù
  • on time
    Á¤°¢¿¡
  • once upon a time
    ¿¾³¯¿¡
  • some other time
    ¾ðÁ¨°¡ µý³¯¿¡(=some other day)
  • some time
    ¾ðÁ¨°¡,Àá½Ã
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á